Autres langues SpectraCure AB

Actions

SPEC

SE0007158118

Equipement et technologie médicale avancés

Temps Différé Nasdaq Stockholm 09:07:56 26/08/2026			Varia. 5j.	Varia. 1 janv.
0,0310 ^SEK	-2,82%		-10,42%	-79,59%

24/08	Dix actions ont atteint aujourd'hui un nouveau plus bas sur 52 semaines à la Bourse de Stockholm	FW
21/08	SpectraCure AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

21/08	SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
01/06	Spectracure appoints Fata Mrsic as CFO
27/05	SpectraCure Q1 net loss after tax SEK 6.1 mln
27/05	SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	SpectraCure AB Reports Earnings Results for the Full Year Ended December 31, 2025
05/05	SpectraCure AB Auditor Raises 'Going Concern' Doubt
27/02	SpectraCure Q4 loss after tax widens to SEK 7.56 mln
26/01	Spectracure signs agreement with Rostock Hospital for prostate cancer study
15/01	Spectracure to get SEK 31.3 mln if all TO5 warrants utilized
01/12	SpectraCure : Interview with CEO Johannes Swartling and Jörgen Wennberg, Chairman of the Board
13/11	SpectraCure Q3 net loss SEK 35 mln
13/11	SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
04/11	Spectracure says study shows significant PSA reduction in prostate cancer patients
21/10/25	Spectracure signs agreement with Cheplapharm for verteporfin supply
13/10/25	Spectracure Q-Pro patent approved in Japan
08/10/25	Spectracure gets approval to commence clinical trial
01/10/25	SpectraCure appoints Johannes Swartling as CEO
22/09/25	Spectracure reports positive results in prostate cancer study
15/08/25	Spectracure Q2 loss after tax SEK 7.2 mln
15/08/25	SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
20/06/25	SpectraCure Rights Issue Subscribed To 58.10%
16/06/25	SpectraCure Announces Preliminary Results From Prostate Cancer Study
05/06/25	Spectracure Gets Approval From German Drug Authority For Prostate Cancer Study
28/05/25	SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2025
27/05/25	Spectracure Signs Deal With Cologne University For Prostate Cancer Study